MK 5108

Drug Profile

MK 5108

Alternative Names: MK-5108; VX-689

Latest Information Update: 12 May 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Merck & Co
  • Class Antineoplastics
  • Mechanism of Action Aurora kinase A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 23 Mar 2011 Phase-I development is ongoing in USA (NCT00543387)
  • 08 Jun 2010 Adverse events, efficacy and pharmacokinetics data from a phase I trial in late-stage and/or refractory solid tumours presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)
  • 12 Jul 2007 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top